ADVOCATE. CONNECT. INNOVATE.

Category Archives: CLSA Wire

New Legislator Spotlight: Assemblyman Robert Rivas

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Assemblymember Robert Rivas (D-Salinas). We look forward to working with Assemblymember Rivas and his team to advance policies that improve patient health and bring positive change for California patients and their families.

New Legislator Spotlight: State Senator María Elena Durazo

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Senator María Elena Durazo (D-Los Angeles). We look forward to working with Senator Durazo and her team to advance policies that improve patient health and bring positive change for California patients and their families.

New Legislator Spotlight: Congressman Mike Levin (D-San Juan Capistrano)

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Congressman Mike Levin (D-San Juan Capistrano). We look forward to working with Congressman Levin and his team to advance policies that improve patient health and bring positive change for California patients and their families.

CLSA Submits Recommendations to House W&M and E&C Leadership on Lowering Medicare Part D Costs for Seniors

Late last month, House Ways and Means Committee Chairman Richard Neal (D-Mass.) and Ranking Member Kevin Brady (R-Texas), and House Energy and Commerce Committee Chairman Frank Pallone (D-N.J.) and Ranking Member Greg Walden (R-Ore.), released a discussion draft text of legislation proposing updates to reform and improve the Medicare Part D program. In coordination with our membership, CLSA submitted comments to Committee Leadership in support of the concept of a cap or limit on the amount that seniors pay out-of-pocket for prescription drugs in Part D.

CLSA Endorses SEC-proposed Changes to Sarbanes-Oxley to Provide Regulatory Relief to Small & Emerging Companies

In May 2019, the Securities and Exchange Commission (SEC) proposed a new rule to expand the universe of small public companies exempt from Sarbanes-Oxley (SOX) Section 404(b) to companies with annual revenues of less than $100 million. SOX 404(b) was established with the intent to protect investors against corporate fraud by increasing the quality of a company’s financial reporting via enhanced transparency and auditor oversight of internal control systems.

CLSA Applauds U.S. House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act

Today, CLSA issued a statement applauding the Congressional passage of S. 1379, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019, legislation that is key to strengthening our national preparedness and response for public health emergencies and accelerating medical countermeasure research and development. Share links below and more information attached.